Portage Biotech Stock Secures Future on Nasdaq After Meeting Equity Requirements

Rhea-AI Filing Summary

Portage Biotech has successfully regained compliance with Nasdaq Capital Market's minimum stockholders' equity requirement, as announced in a Form 6-K filed on June 28, 2025. The company received official notice from Nasdaq on June 24, 2025, confirming their compliance status and closing the previously announced listing matter.

Key points from the filing:

• Filing incorporates by reference into Form S-8 (File No. 333-275842) and Form F-3 (File No. 333-286961) registration statements
• Company maintains its listing on the Nasdaq Capital Market
• Press release dated June 25, 2025, included as Exhibit 99.1
• Document signed by CFO Andrea Park

This development is significant for investors as it confirms Portage Biotech's continued compliance with Nasdaq listing requirements, ensuring maintained access to public markets and investor visibility.

Positive

• Company regained compliance with Nasdaq's minimum stockholders' equity requirement, resolving previous listing concerns and maintaining its Nasdaq Capital Market listing status

Negative

• None.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2025

 

Commission File Number: 001-40086

 

PORTAGE BIOTECH INC.

(Translation of registrant's name into English)

 

Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F [ X ]             Form 40-F [ ]

 

 

 

INCORPORATION BY REFERENCE

 

This report on Form 6-K (including any exhibits attached hereto) shall be deemed to be incorporated by reference into the registration statement on Form S-8 (File No. 333-275842) and Form F-3 (File No. 333-286961) of Portage Biotech Inc. (including any prospectuses forming a part of such registration statement) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 

 

 

On June 25, 2025, Portage Biotech Inc. (the “Company”) issued a press release announcing that on June 24, 2025, the Company received notice from The Nasdaq Stock Market, LLC, indicating that the Company has regained compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Accordingly, the previously announced listing matter has been closed. A copy of the press release is filed herewith as Exhibit 99.1.

 

Exhibits

 

Exhibit Number	 	Description
 	 	 
99.1	 	Press Release dated June 25, 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 	Portage Biotech Inc.
 	(Registrant)
 	 
 	 
Date: June 25, 2025	/s/ Andrea Park
 	Andrea Park Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FAQ

Why did PRTG file a 6-K on June 28, 2025?

PRTG filed a 6-K to announce that on June 24, 2025, the company received notice from Nasdaq confirming it has regained compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. This resolved a previously announced listing matter.

Has PRTG resolved its Nasdaq listing compliance issues?

Yes, as of June 24, 2025, PRTG has regained compliance with Nasdaq's minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. The company received official notice from Nasdaq and the previously announced listing matter has been closed.

What stock exchange is PRTG listed on in 2025?

PRTG is listed on The Nasdaq Capital Market, as confirmed by the 6-K filing which discusses the company's compliance with Nasdaq listing requirements.

What SEC forms does Portage Biotech (PRTG) file for annual reports?

According to the 6-K filing, Portage Biotech Inc. (PRTG) files annual reports using Form 20-F, as indicated by the checkbox disclosure in the filing.

Who is the CFO of Portage Biotech (PRTG) as of June 2025?

Andrea Park serves as the Chief Financial Officer of Portage Biotech (PRTG), as evidenced by her signature on the 6-K filing dated June 25, 2025.